| Study | Population | Intervention | Comparison | Comments |
|---|---|---|---|---|
| Primary care (K=5, N=1,184) | ||||
|
Bjerkenstedt 2005 RCT Sweden |
Primary care N=115 Baseline severity: More severe Mean age (years): 50.9 Sex (% female): 79 Ethnicity (% BME): 0 | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Doogan 1994 RCT UK |
Primary care N=200 Baseline severity: More severe Mean age (years): 45.7 Sex (% female): 68 Ethnicity (% BME): NR | Sertraline 50-100mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Lepola 2003 RCT Belgium, Canada, Finland, France, Norway, Sweden, Switzerland & UK |
Primary care N=469 Baseline severity: More severe Mean age (years): 43.3 Sex (% female): 72 Ethnicity (% BME): NR | Escitalopram 10-20mg/day or citalopram 20-40mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Lopez-Rodriguez 2004 RCT South America |
Primary care N=20 Baseline severity: More severe Mean age (years): 31.9 Sex (% female): NR Ethnicity (% BME): NR | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 9 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Wade 2002 RCT Canada, Estonia, France, Netherlands & UK |
Primary care N=380 Baseline severity: More severe Mean age (years): 40.5 Sex (% female): 76 Ethnicity (% BME): 3 | Escitalopram 10mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
| Secondary care (K=78, N=18,070) | ||||
|
29060 07 001a RCT US |
Secondary care N=25 Baseline severity: More severe Mean age (years): 42.5 Sex (% female): 56 Ethnicity (% BME): NR | Paroxetine 10-60mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Andreoli 2002/Dubini 1997/Massana 1998_study 1 RCT Brazil, France, Ireland, Italy, Poland, and UK |
Secondary care N=255 Baseline severity: More severe Mean age (years): 42.2 Sex (% female): 60 Ethnicity (% BME): NR | Fluoxetine 20-40mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Baune 2018 RCT Estonia, Finland, Germany, & Lithuania |
Secondary care N=104 Baseline severity: More severe Mean age (years): 45.7 Sex (% female): 64 Ethnicity (% BME): 2 | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Binnemann 2008 RCT US, Serbia and Montenegro, & the Russian Federation |
Secondary care N=82 Baseline severity: More severe Mean age (years): 49 Sex (% female): 39 Ethnicity (% BME): NR | Sertraline 100mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Bose 2008 RCT US |
Secondary care N=267 Baseline severity: More severe Mean age (years): 68.3 Sex (% female): 59 Ethnicity (% BME): 11 | Escitalopram 10-20mg/day | Placebo |
Treatment duration (weeks): 12 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Burke 2002 RCT US |
Secondary care N=491 Baseline severity: More severe Mean age (years): 40.1 Sex (% female): 65 Ethnicity (% BME): NR | Escitalopram 10mg/day or 20mg/day, or citalopram 40mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Byerley 1988a RCT US |
Secondary care N=61 Baseline severity: More severe Mean age (years): 38.3 Sex (% female): 68 Ethnicity (% BME): NR | Fluoxetine 40-80mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Claghorn 1992a RCT US |
Secondary care N=59 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 10-50mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Claghorn 1992b RCT US |
Secondary care N=72 Baseline severity: More severe Mean age (years): 35 Sex (% female): 32 Ethnicity (% BME): NR | Paroxetine 10-50mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Clayton 2006_study 1 RCT US |
Secondary care N=283 Baseline severity: More severe Mean age (years): 35 Sex (% female): 61 Ethnicity (% BME): 35 | Escitalopram 10-20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Clayton 2006_study 2 RCT US |
Secondary care N=286 Baseline severity: More severe Mean age (years): 36.5 Sex (% female): 56 Ethnicity (% BME): 27 | Escitalopram 10-20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
CL3-20098-022 RCT Europe |
Secondary care N=286 Baseline severity: More severe Mean age (years): 43 Sex (% female): 67 Ethnicity (% BME): NR | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
CL3-20098-023 RCT Cross-continental |
Secondary care N=275 Baseline severity: More severe Mean age (years): 41.1 Sex (% female): 75 Ethnicity (% BME): NR | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
CL3-20098-024 RCT Cross-continental |
Secondary care N=306 Baseline severity: More severe Mean age (years): 41.5 Sex (% female): 73 Ethnicity (% BME): NR | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Detke 2004b RCT US |
Secondary care N=179 Baseline severity: More severe Mean age (years): 42.9 Sex (% female): 71 Ethnicity (% BME): 0 | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Dube 2010 RCT India, US, Mexico & Romania |
Secondary care N=200 Baseline severity: More severe Mean age (years): 36.5 Sex (% female): 44 Ethnicity (% BME): NR | Escitalopram 10-20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Dunbar 1993 RCT US |
Secondary care N=341 Baseline severity: More severe Mean age (years): 41 Sex (% female): 51 Ethnicity (% BME): NR | Paroxetine 10-50mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Eli Lilly HMAT-Aa RCT US |
Secondary care N=179 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Emsley 2018 RCT Bulgaria, Estonia, Finland, France, Republic of Korea, Malaysia, Mexico, Poland, Romania, & Slovakia |
Secondary care N=206 Baseline severity: More severe Mean age (years): 70.6 Sex (% female): 75 Ethnicity (% BME): NR | Escitalopram 10mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Fabre 1992a RCT US |
Secondary care N=80 Baseline severity: More severe Mean age (years): 35.8 Sex (% female): 59 Ethnicity (% BME): NR | Paroxetine 10-50mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Fabre 1995a RCT US |
Secondary care N=369 Baseline severity: More severe Mean age (years): 37.6 Sex (% female): 53 Ethnicity (% BME): 9 | Sertraline 50mg/day, 100mg/day, or 200mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Fava 1998a RCT US |
Secondary care N=128 Baseline severity: More severe Mean age (years): 41.3 Sex (% female): 51 Ethnicity (% BME): NR | Paroxetine 20-50mg/day or fluoxetine 20-80mg/day | Placebo |
Treatment duration (weeks): 12 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Fava 2005 RCT US |
Secondary care N=90 Baseline severity: More severe Mean age (years): 37.2 Sex (% female): 59 Ethnicity (% BME): NR | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 12 Outcomes (for primary versus secondary care subgroup analysis):
|
|
FDA 245 (EMD 68 843-010) RCT US |
Secondary care N=191 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
FDA 246 (SB 659746-003) RCT US |
Secondary care N=246 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR | Citalopram 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Forest Laboratories 2000 RCT US |
Secondary care N=386 Baseline severity: More severe Mean age (years): 42 Sex (% female): 52 Ethnicity (% BME): NR | Escitalopram 10-20mg/day or citalopram 20-40mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Forest Research Institute 2005 RCT US |
Secondary care N=409 Baseline severity: More severe Mean age (years): 40 Sex (% female): 56 Ethnicity (% BME): NR | Escitalopram 10-20mg/day or sertraline 50-200mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Golden 2002_448 RCT US |
Secondary care N=315 Baseline severity: More severe Mean age (years): 39 Sex (% female):NR Ethnicity (% BME): NR | Paroxetine 20-62.5mg/day | Placebo |
Treatment duration (weeks): 12 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Golden 2002_449 RCT US |
Secondary care N=330 Baseline severity: More severe Mean age (years): 41.2 Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 20-62.5mg/day | Placebo |
Treatment duration (weeks): 12 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Goldstein 2002a RCT US |
Secondary care N=103 Baseline severity: More severe Mean age (years): 40.9 Sex (% female): 65 Ethnicity (% BME): 21 | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Goldstein 2004a RCT US |
Secondary care N=176 Baseline severity: More severe Mean age (years): 40 Sex (% female): 64 Ethnicity (% BME): 22 | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Gual 2003 RCT Spain |
Secondary care N=83 Baseline severity: More severe Mean age (years): 46.7 Sex (% female): 47 Ethnicity (% BME): NR | Sertraline 50-150mg/day | Placebo |
Treatment duration (weeks): 24 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Higuchi 2009a RCT Japan |
Secondary care N=294 Baseline severity: More severe Mean age (years): 38.3 Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 20-40mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Hirayasu 2011a RCT Japan |
Secondary care N=310 Baseline severity: More severe Mean age (years): 34.6 Sex (% female): NR Ethnicity (% BME): NR | Escitalopram 10mg/day or 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Hirayasu 2011b RCT Japan |
Secondary care N=485 Baseline severity: More severe Mean age (years): 36.2 Sex (% female): NR Ethnicity (% BME): NR | Escitalopram 10mg/day or 20mg/day, or paroxetine 20-40mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Jefferson 2000 RCT US |
Secondary care N=415 Baseline severity: More severe Mean age (years): 39.9 Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 25mg/day, or citalopram 20mg/day or 40mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Kasper 2012 RCT Russia & Austria |
Secondary care N=211 Baseline severity: More severe Mean age (years): 41.9 Sex (% female): 71 Ethnicity (% BME): 0 | Escitalopram 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Katz 2004 RCT US |
Secondary care N=53 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 20-60mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Keller 2006_Study 062 RCT Cross-continental |
Secondary care N=325 Baseline severity: More severe Mean age (years):41 Sex (% female): 67 Ethnicity (% BME): 43 | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Kramer 1998 RCT US |
Secondary care N=142 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Kranzler 2006_Group A RCT US |
Secondary care N=189 Baseline severity: More severe Mean age (years): 42.9 Sex (% female): 35 Ethnicity (% BME): 10 | Sertraline 50-200mg/day | Placebo |
Treatment duration (weeks): 10 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Lam 2016b RCT Canada |
Secondary care N=61 Baseline severity: More severe Mean age (years): 36.8 Sex (% female): 72 Ethnicity (% BME): NR | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Macias-Cortes 2015 RCT Mexico |
Secondary care N=89 Baseline severity: More severe Mean age (years): 49 Sex (% female): 100 Ethnicity (% BME): 100 | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Mathews 2015 RCT US |
Secondary care N=579 Baseline severity: More severe Mean age (years): 42.3 Sex (% female): 57 Ethnicity (% BME): 32 | Citalopram 40mg/day | Placebo |
Treatment duration (weeks): 10 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Mendels 1999 RCT US |
Secondary care N=180 Baseline severity: More severe Mean age (years): 43 Sex (% female): 33 Ethnicity (% BME): 13 | Citalopram 20-80mg/day | Placebo |
Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Miller 1989a RCT UK |
Secondary care N=47 Baseline severity: More severe Mean age (years): 42.5 Sex (% female): 68 Ethnicity (% BME): NR | Paroxetine 30mg/day | Placebo |
Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Montgomery 1992 RCT UK |
Secondary care N=199 Baseline severity: More severe Mean age (years): 44 Sex (% female): 69 Ethnicity (% BME): NR | Citalopram 20mg/day or 40mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Mundt 2012 RCT US |
Secondary care N=165 Baseline severity: More severe Mean age (years): 37.8 Sex (% female): 63 Ethnicity (% BME): 24 | Sertraline 50-100mg/day | Placebo |
Treatment duration (weeks): 4 Outcomes (for primary versus secondary care subgroup analysis):
|
|
MY-1042/BRL-029060/CPMS-251 RCT US |
Secondary care N=254 Baseline severity: More severe Mean age (years): 41.9 Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 20-50mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
MY-1042/BRL-029060/1 (PAR 128) RCT US |
Secondary care N=848 Baseline severity: More severe Mean age (years): 41.8 Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 20-50mg/day or fluoxetine 20-80mg/day | Placebo |
Treatment duration (weeks): 12 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Nemeroff 2007a RCT US |
Secondary care N=206 Baseline severity: More severe Mean age (years): 39.1 Sex (% female): 61 Ethnicity (% BME): 7 | Fluoxetine 20-60mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Nierenberg 2007a RCT US |
Secondary care N=411 Baseline severity: More severe Mean age (years): 43 Sex (% female): 66 Ethnicity (% BME): 21 | Escitalopram 10mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
NKD20006 (NCT00048204) RCT US |
Secondary care N=250 Baseline severity: More severe Mean age (years): 38 Sex (% female): 60 Ethnicity (% BME): NR | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Nyth 1992 RCT Denmark, Norway & Sweden |
Secondary care N=149 Baseline severity: More severe Mean age (years): 76.7 Sex (% female): 69 Ethnicity (% BME): NR | Citalopram 10-30mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Olie 1997 RCT France |
Secondary care N=258 Baseline severity: More severe Mean age (years): 43.8 Sex (% female): 63 Ethnicity (% BME): 1 | Sertraline 50-200mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
PAR 01 001 (GSK & FDA) RCT US |
Secondary care N=50 Baseline severity: More severe Mean age (years): 43.1 Sex (% female): 35 Ethnicity (% BME): NR | Paroxetine 10-50mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Perahia 2006b RCT Bulgaria, Croatia, Hungary, Poland, Romania, Russia, & Slovakia |
Secondary care N=196 Baseline severity: More severe Mean age (years): 45.2 Sex (% female): 68 Ethnicity (% BME): 0 | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Peselow 1989aa RCT US |
Secondary care N=73 Baseline severity: More severe Mean age (years): 43.2 Sex (% female): 38 Ethnicity (% BME): NR | Paroxetine 10-50mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Peselow 1989ba RCT US |
Secondary care N=82 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR | Paroxetine 20-50mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Rapaport 2009 RCT US |
Secondary care N=357 Baseline severity: More severe Mean age (years): 67.5 Sex (% female): 62 Ethnicity (% BME): 17 | Paroxetine 25mg/day | Placebo |
Treatment duration (weeks): 10 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Ratti 2011_study 096 RCT 11 countries in Europe and Latin America |
Secondary care N=236 Baseline severity: More severe Mean age (years): 44 Sex (% female): 72 Ethnicity (% BME): NR | Paroxetine 20-30mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Ravindran 1995 RCT Canada |
Secondary care N=66 Baseline severity: More severe Mean age (years): 38.9 Sex (% female): 62 Ethnicity (% BME): NR | Sertraline 50-200mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Reimherr 1990a RCT US & Canada |
Secondary care N=299 Baseline severity: More severe Mean age (years): 39.6 Sex (% female): 53 Ethnicity (% BME): 8 | Sertraline 20-200mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Rickels 1992 RCT US |
Secondary care N=111 Baseline severity: More severe Mean age (years): 44.7 Sex (% female): 48 Ethnicity (% BME): NR | Paroxetine (dose NR) | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Rudolph 1999a RCT US |
Secondary care N=201 Baseline severity: More severe Mean age (years): 40 Sex (% female): 66 Ethnicity (% BME): NR | Fluoxetine 20-60mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
SER 315 (FDA)a RCT Europe |
Secondary care N=165 Baseline severity: More severe Mean age (years): 42.0 Sex (% female): 72 Ethnicity (% BME): NR | Sertraline 50-200mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Sheehan 2009ba RCT US |
Secondary care N=194 Baseline severity: More severe Mean age (years): 38.8 Sex (% female): 66 Ethnicity (% BME): NR | Fluoxetine 60-80mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Smith 1992 RCT US |
Secondary care N=77 Baseline severity: More severe Mean age (years): 44.8 Sex (% female): 50 Ethnicity (% BME): NR | Paroxetine 10-50mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Stark 1985a RCT US |
Secondary care N=354 Baseline severity: More severe Mean age (years): 40.5 Sex (% female): 68 Ethnicity (% BME): NR | Fluoxetine 60-80mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Study 62b (FDA) RCT Country NR |
Secondary care N=356 Baseline severity: More severe Mean age (years): 40 Sex (% female): 57 Ethnicity (% BME): NR | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Study F1J-MC-HMAQ- Study Group Ba RCT US |
Secondary care N=112 Baseline severity: More severe Mean age (years): 40.8 Sex (% female): NR Ethnicity (% BME): NR | Fluoxetine 20mg/day | Placebo |
Treatment duration (weeks): 10 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Tollefson 1993/1995 RCT US |
Secondary care N=671 Baseline severity: More severe Mean age (years): 67.7 Sex (% female): 55 Ethnicity (% BME): 6 | Fluoxetine maximum 20mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Valle-Cabrera 2018 RCT Cuba |
Secondary care N=77 Baseline severity: More severe Mean age (years): 45.2 Sex (% female): 92 Ethnicity (% BME): NR | Sertraline 50-200mg/day | Placebo |
Treatment duration (weeks): 10 Outcomes (for primary versus secondary care subgroup analysis):
|
|
VEN XR 367 (FDA)b RCT Europe |
Secondary care N=164 Baseline severity: More severe Mean age (years): NR Sex (% female): 61 Ethnicity (% BME): NR | Paroxetine 20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis): Depression symptoms change score |
|
Wang 2014c RCT Canada, China, Finland, South Korea, Malaysia, Mexico, The Philippines, South Africa, & Spain |
Secondary care N=314 Baseline severity: More severe Mean age (years): 40 Sex (% female): 71 Ethnicity (% BME): 46 | Escitalopram 10-20mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
WELL AK1A4006 RCT US |
Secondary care N=309 Baseline severity: More severe Mean age (years): 37.9 Sex (% female): NR Ethnicity (% BME): NR | Fluoxetine 20-60mg/day | Placebo |
Treatment duration (weeks): 8 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Wernicke 1987 RCT US |
Secondary care N=356 Baseline severity: More severe Mean age (years): 39.8 Sex (% female): 57 Ethnicity (% BME): NR | Fluoxetine 20mg/day, 40mg/day, or 60mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
|
Wernicke 1988 RCT US |
Secondary care N=267 Baseline severity: More severe Mean age (years): NR Sex (% female): NR Ethnicity (% BME): NR | Fluoxetine 20mg/day or 40mg/day | Placebo |
Treatment duration (weeks): 6 Outcomes (for primary versus secondary care subgroup analysis):
|
Three-armed trial but where possible the demographics reported here are for only the two relevant arms.
Four-armed trial but where possible the demographics reported here are for only the two relevant arms.
BME: black, minority, ethnic; K: number of studies; mg: milligrams; N: number of participants; NR: not reported; RCT: randomised controlled trial.
From: Service delivery Models and settings for delivery of services
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.